Strides Shasun is currently trading at Rs. 1395.45, up by 32.65 points or 2.40% from its previous closing of Rs. 1362.80 on the BSE.
The scrip opened at Rs. 1390.00 and has touched a high and low of Rs. 1412.45 and Rs. 1386.00 respectively. So far 15654 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1412.45 on 18-Nov-2015 and a 52 week low of Rs. 720.00 on 25-Nov-2014.
Last one week high and low of the scrip stood at Rs. 1412.45 and Rs. 1275.00 respectively. The current market cap of the company is Rs. 10990.02 crore.
The promoters holding in the company stood at 27.65% while Institutions and Non-Institutions held 44.42% and 27.94% respectively.
Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Dutasteride Capsules, 0.5 mg. The product is ready for Day 1 launch. The product will be manufactured at the company’s Oral dosage facility at Bangalore and marketed by Strides Shasun in the US Market.
The US market for Dutasteride Capsules is approximately $470 million. The product has gone off patent on November 20, 2015 and Strides Shasun is amongst the first wave of generic players to receive this approval.
Strides Shasun is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: